Key insights
- Tempus AI CEO Eric Lefkofsky sold $7.76 million in stock, despite the company's recent 9.3% stock gain and strong revenue growth. While the AI healthcare firm shows impressive top-line expansion, InvestingPro analysis suggests it may be overvalued. The sale, executed via a pre-arranged trading plan, could signal a lack of confidence from management at current price levels, potentially creating a bearish sentiment for the stock.
Eric P. Lefkofsky, CEO and Chairman of Tempus AI, Inc. (NASDAQ:TEM), disposed of Class A Common Stock valued at $7,763,312 on May 27, 2026. The shares were sold at weighted average prices ranging from $46.17 to $46.89. The stock currently trades at $50.46, reflecting a strong 9.3% gain over the past week, though InvestingPro analysis suggests the company appears overvalued at current levels. The AI healthcare company, valued at $9.2 billion, has demonstrated impressive 70% revenue growth despite ongoing profitability challenges.
The transactions involved a total of 166,250 shares and were executed indirectly through entities managed by Mr. Lefkofsky. Gray Media, LLC sold 33,250 shares, comprising 8,932 shares at a weighted average price of $46.17 (with individual transaction prices ranging from $45.53 to $46.52) and 24,318 shares at a weighted average price of $46.89 (with individual transaction prices ranging from $46.53 to $47.47). Blue Media, LLC sold 133,000 shares, consisting of 35,721 shares at a weighted average price of $46.17 (with individual transaction prices ranging from $45.53 to $46.52) and 97,279 shares at a weighted average price of $46.89 (with individual transaction prices ranging from $46.53 to $47.47).
All dispositions were made pursuant to a Rule 10b5-1 trading plan, which Mr. Lefkofsky adopted on March 4, 2025. For deeper insights into TEM’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available among 1,400+ US equities covered on InvestingPro.
In other recent news, Tempus AI, Inc. announced significant developments regarding its medical technology. The company revealed the results of its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting. These models are based on extensive data, including 2.5 million longitudinal records and over 250 million pages of clinical notes. Additionally, Tempus AI received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform. This approval positions Tempus as the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. The company also expanded its Next platform to include six new cancer types, broadening its clinical applications. These updates highlight Tempus AI’s ongoing advancements in genomic testing and artificial intelligence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.